University College London (UCL)
324 articles with University College London (UCL)
-
Scientists from the Francis Crick Institute and University College London say they have, for the first time, conclusively explained how air pollution leads to lung cancer in nonsmokers.
-
Agilent Announces Thought Leader Award to Gerhardt Attard at University College London (UCL)
8/2/2022
Agilent Technologies Inc. announced that Professor Gerhardt Attard has been selected to receive a prestigious Agilent Thought Leader Award.
-
Freeline Therapeutics' hemophilia B drug demonstrated the strong possibility that a single injection of FLT180a, an experimental gene therapy, can reduce or eliminate the need for weekly injections.
-
Lenire Biosciences Completes License Agreement with University College London for VSN16R, A Novel Clinical Candidate Treatment for Fragile X Syndrome
6/16/2022
Lenire Biosciences Inc., a biopharmaceutical company developing novel treatments for Fragile X Syndrome (FXS) and related disorders, today announced that it has agreed to a license from UCL (University College London) for VSN16R, a small molecule positive modulator of large-conductance, calcium-activated potassium (“BK”) channels, as a novel therapy for FXS.
-
An article in Nature explains that ten genes, upon severe mutation that alters genetic function, are linked to an increased risk of the development of schizophrenia.
-
BrainStorm Cell Therapeutics’ NurOwn has taken the amyotrophic lateral sclerosis (ALS) community by storm with new genetic data from its Phase III trial.
-
There's always more to learn about Parkinson's, and researchers discovered a specialized group of neurons associated with the disease.
-
Researchers have unlocked a key mechanism behind the gene encoding protein UNC13A which could provide new treatment options for ALS and FTD.
-
Scientists Explore SARS-CoV-2 Mega Vaccine
11/11/2021
Scientists are conducting research into the possibility of creating a vaccine that activates T cells that targets not just SARS-CoV-2 but also its variations, even the ones that cause common colds. -
UPDATE - UCSF QBI and University College, London Identify Mutations in “U.K.” Strain of Coronavirus SARS-CoV-2 Responsible for Enhanced Transmissibility and Infectivity
6/7/2021
Findings show key mutations and evolution of U.K. SARS-CoV-2 compared to earlier lineages account for upregulation of innate immune antagonists, which hamper immune response and allow for increased viral replication and duration of infection
-
UCSF QBI and University College, London Identify Mutations in “U.K.” Strain of Coronavirus SARS-CoV-2 Responsible for Enhanced Transmissibility and Infectivity
6/7/2021
Findings show key mutations and evolution of U.K. SARS-CoV-2 compared to earlier lineages account for upregulation of innate immune antagonists, which hamper immune response and allow for increased viral replication and duration of infection
-
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
-
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
-
Qualigen Therapeutics Secures Option to Negotiate License for G-Quadruplex Anti-Cancer Technology from UCL
3/1/2021
Qualigen Therapeutics, Inc. (NASDAQ: QLGN) , a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral diseases, announced today it has entered into a Material Evaluation and Option Agreement with the University College London (UCL) to advance development of and potentially expand toward future commercial uses of Qualigen's leading anticancer drug candidate AS1411-GNP
-
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
-
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
-
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
-
Theragnostics reports positive clinical trial results from prostate cancer study
10/2/2019
Study evaluates clinical utility of 68Ga THP-PSMA PET/CT imaging in men with newly diagnosed and recurrent prostate cancer
-
cTAP Publishes Comprehensive Analysis of the North Star Ambulatory Assessment (NSAA), a Newly Adopted Primary Outcome Measure in Clinical Trials of Patients with Duchenne Muscular Dystrophy
9/26/2019
The collaborative Trajectory Analysis Project, a multi-stakeholder, global coalition in Duchenne muscular dystrophy, publishes research in the journal PLOS ONE providing quantitative insights to assist the design and analysis of clinical trials in patients with DMD.
-
AstronauTx secures £6.5 million investment for new approach to dementia therapeutics
8/12/2019
A new UK-based biotech company, AstronauTx Ltd, which builds on the work from the Alzheimer’s Research UK UCL Drug Discovery Institute (DDI), has received an investment of £6.5 million from the Dementia Discovery Fund (DDF).